Determinants of sustained virological suppression in indigent, HIV-infected patients: is single protease inhibitor-based antiretroviral therapy truly highly active?
- PMID: 15248135
- DOI: 10.1310/JQ8U-6KVB-9JCG-JL51
Determinants of sustained virological suppression in indigent, HIV-infected patients: is single protease inhibitor-based antiretroviral therapy truly highly active?
Abstract
Background: Effective virological suppression with HAART is dependent on strict adherence to therapy. Compliance with therapy is influenced by clinical and psychosocial factors.
Method: We performed a retrospective study investigating determinants of effective virological suppression, defined as <400 RNA at 11-13 months of HAART, in an urban indigent population. The study included 366 new patients presenting for care to the Thomas Street Clinic, Houston, Texas, between April and December 1998. Median age, CD4 count, and viral load (VL) of the study population were 37.5 years, 189 cells/mm(3), and 53,000, respectively. Thirty-nine percent had AIDS, 20% had cocaine-positive drug screens, and 64% were antiretroviral naïve. Two hundred and sixty-seven patients were started on HAART. Thirty-four percent showed virological suppression.
Results: In multivariate analysis, adherence to HAART, care by experienced primary provider, baseline VL <100,000 copies/mL, age >35 years, and no active substance use were associated with virological suppression. Rates of virological suppression with HAART are unacceptably low in this urban indigent population.
Conclusion: Low rates of virological suppression are primarily due to lack of adherence rather than late utilization of care among ethnic minorities. Single protease-inhibitor-based antiretroviral therapy does not appear to be highly active in this patient population.
Similar articles
-
Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.Antivir Ther. 2004 Oct;9(5):713-9. Antivir Ther. 2004. PMID: 15535408
-
Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.Antivir Ther. 2008;13(7):927-36. Antivir Ther. 2008. PMID: 19043927
-
Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.HIV Med. 2006 Mar;7(2):99-104. doi: 10.1111/j.1468-1293.2006.00347.x. HIV Med. 2006. PMID: 16420254
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Beyond virological suppression: the role of adherence in the late HAART era.Antivir Ther. 2012;17(5):785-92. doi: 10.3851/IMP2084. Epub 2012 Mar 13. Antivir Ther. 2012. PMID: 22414552 Review.
Cited by
-
Short-term discontinuation of HAART regimens more common in vulnerable patient populations.AIDS Res Hum Retroviruses. 2008 Nov;24(11):1347-55. doi: 10.1089/aid.2008.0083. AIDS Res Hum Retroviruses. 2008. PMID: 19032064 Free PMC article.
-
The population effectiveness of highly active antiretroviral therapy: are good drugs good enough?Curr HIV/AIDS Rep. 2005 Nov;2(4):177-83. doi: 10.1007/s11904-005-0013-7. Curr HIV/AIDS Rep. 2005. PMID: 16343375 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous